Syndicated Studies
Sometimes the market evolves so quickly, and with such complexity, that companies struggle to stay abreast of the changes. The Zitter Group’s syndicated, multi-client market research products were developed to help companies understand the environment as it evolves.
Each research product combines the same methodological rigor and rich market expertise that inform our primary market research projects. We use large samples of 100 or more managed care decision-makers, carefully constructed to ensure reliable, representative results. We also work closely with our clients to identify and frame key issues for deeper study and analysis. As a result, our syndicated research doesn’t have that off-the-shelf feel – it reflects the top concerns of the top companies in the industry.
We believe that by working with our clients to target the key issues, we ensure that the results produce helpful insights into market dynamics.
The Managed Care Message Monitor
The Managed Care Message Monitor is an ongoing survey of payer decision makers reporting payer descriptions and perceptions of visits by biopharmaceutical representatives. The MCMM offers significant insight into the value assigned by payers to a company’s products, activities, and services.
The Managed Care Biologics and Injectables Index
Produced twice a year, the Managed Care Biologics and Injectables Index offers the largest and most detailed analysis of managed care’s approach to injectable therapies.
The Managed Care Oncology Index
Produced twice a year, the Managed Care Oncology Index is the most comprehensive and up-to-date analysis of the major trends underway in the evolving payer market for oncology.
The Managed Care Benefit Design Index
Produced twice a year, the Managed Care Benefit Design Index offers a detailed examination of employer/managed care collaboration when establishing benefit design and healthcare offerings.
Click here for TZG Index Samples
Biotechnology and Managed Care
Managed care organizations continue to grow more sophisticated in their management of biotechnology products. For a detailed analysis of the evolution of managed care’s approach to specialty products, download Tom Baker’s article “5 Stages of Biotechnology Management” from the February 2005 issue of Biotechnology Healthcare.To review some of our past research findings from the biotechnology market, download Tom Baker’s article “Specialty Therapies Lose Special Status” from the September 2004 issue of Pharmaceutical Executive.